Anticoagulation in portal vein thrombosis among patients with cirrhosis; myths vs evidence

Create Account

Availability

Registration Required

Online Meeting

Sep 08, 2026 12:00 PM - 1:00 PM ET

Cost

$0.00

Credit Offered

No Credit Offered

Description
Learning Objectives
Faculty and Disclosures
Privacy Policy

Management of portal vein thrombosis in portal hypertension, including selection of the optimal candidates, specific anticoagulant and duration of anticoagulation are important topics that are encountered in daily practice. However, these decisions are not straight forward and need to take into account several aspects of each case, including transplant candidacy, severity of liver disease and extend of the portal vein thrombosis. Additionally, patients with cirrhosis are at increased risk of bleeding events, and risks and benefits of anticoagulation need to be individually assessed in each patient. This webinar will address common questions and controversies in the management of such patients. It is intended for hepatologists, gastroenterologists, physician assistants, nurse practitioners, fellows and trainees. Others with an interest in managing patients with portal hypertension and the duration of anticoagulation are invited to attend.

Upon completion of this activity, participants should be able to:

• Identify appropriate patient selection for anticoagulation
• Define the choice and duration of anticoagulation
• Assess bleeding risk assessment

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Patrick G. Northup, MD
Marco Senzolo, MD, PhD
Jessica Davis, MD

https://www.aasld.org/terms-use-and-privacy-policy